2级和3级胶质瘤患者抗癫痫药物撤药的长期随访结果:前瞻性观察研究
该前瞻性多中心观察研究纳入71例2-3级弥漫性胶质瘤患者,比较抗癫痫药物(ASM)撤药与继续用药后癫痫复发的长期结果。48个月和96个月时,撤药组复发累积 incidence 分别为48%和66%,继续用药组分别为28%和52%;两个时间段的风险比均无统计学显著性。作者认为撤药应谨慎,仅在必要时进行。
要点
- 撤药组48个月复发累积发生率为48%,继续用药组为28%。
- 撤药组96个月复发累积发生率为66%,继续用药组为52%。
- 两个时间段内撤药组与继续用药组的复发风险差异均无统计学意义。
核心结论
- 撤药组癫痫复发风险在统计学上未显著高于继续用药组,但撤药组复发比例在临床上较高。
- 统计学差异缺失可能由样本量小解释,需要更大规模研究确认。
- 结果提示ASM撤药应谨慎启动且仅在必要时进行。
研究设计与样本
- 前瞻性多中心观察研究,2014年1月至2016年5月从荷兰3家神经肿瘤门诊招募患者。
- 纳入标准:至少1次癫痫发作并开始ASM;临床和影像学疾病稳定≥12个月;自末次抗肿瘤治疗起无癫痫发作≥12个月,或若末次抗肿瘤治疗后出现癫痫发作,则自末次发作起无癫痫发作≥24个月。
- 共纳入71例患者(39例男性[55%],58例年龄>40岁[82%]);ASM撤药组46例(65%),ASM继续组25例(35%)。
主要发现
- 48个月复发累积发生率:撤药组48%(95% CI 33%-61%)vs 继续组28%(95% CI 12%-46%)。
- 96个月复发累积发生率:撤药组66%(95% CI 48%-78%)vs 继续组52%(95% CI 31%-70%)。
- <48个月期间,以继续组为参照,撤药组病因特异性调整风险比(aHR)为2.32(95% CI 0.93-5.81),p=0.071。
- ≥48个月期间,以继续组为参照,撤药组病因特异性aHR为0.73(95% CI 0.21-2.49),p=0.611。
关键数值与推荐
- 主要结局为癫痫复发时间,采用竞争风险模型估计累积发生率,死亡为竞争事件。
- ASM组比例风险假设不成立,因此构建了两个不同时间段的Cox模型(研究纳入后<48个月和≥48个月)。
- 该研究提供III级证据,表明撤药未显著增加疾病稳定且无癫痫发作>1年的胶质瘤患者的癫痫复发风险,但置信区间不能排除临床上重要的风险增加。
临床怎么用
- 对于疾病稳定且无癫痫发作>1年的2-3级胶质瘤患者,ASM撤药应谨慎启动且仅在必要时进行。
- 撤药组在临床上复发比例较高,决策时需权衡复发风险。
- 需更大规模研究确认这些发现。
局限性
- 原文述样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the long-term results of seizure recurrence after antiseizure medication (ASM) withdrawal vs continuation in patients with diffuse glioma, grades 2 and 3. METHODS: A prospective multicenter observational study was conducted, and patients were recruited from January 2014 until May 2016 from 3 neuro-oncology outpatient clinics in the Netherlands. The main inclusion criteria were as follows: history of ≥1 seizure, for which ASM was started; clinically and radiologically stable disease for ≥12 months; and seizure freedom for ≥12 months from the date of last antitumor treatment or seizure freedom for ≥24 months from the last seizure if seizures occurred after the last antitumor treatment. The primary outcome was time to recurrent seizure. A competing risk model was used to estimate cumulative incidences of recurrent seizure for ASM groups (i.e., ASM withdrawal vs ASM continuation) with death as the competing event. The proportional hazard assumption was violated for the ASM group; therefore, 2 Cox models were constructed for different time intervals (<48 months and ≥48 months since study inclusion). RESULTS: A total of 71 patients were included (39 men [55%] and 58 older than 40 years [82%]); 46 patients with glioma (65%) were in the ASM withdrawal group and 25 (35%) in the ASM continuation group. The cumulative incidence of a recurrent seizure at 48 and 96 months was 48% (95% CI 33%-61%) and 66% (95% CI 48%-78%) for the ASM withdrawal group vs 28% (95% CI 12%-46%) and 52% (95% CI 31%-70%) for the ASM continuation group. The risk of a recurrent seizure differed in the 2 time intervals between the ASM continuation group (reference) and the ASM withdrawal group (cause-specific adjusted hazard ratio [aHR] 2.32 [95% CI 0.93-5.81], p = 0.071, during <48 months, and cause-specific aHR 0.73 [95% CI 0.21-2.49], p = 0.611, during ≥48 months since study inclusion). DISCUSSION: Risk of recurrent seizure when withdrawing ASM was not statistically significantly higher in patients continuing ASM. However, a clinically relevant higher percentage of patients had a recurrent seizure in the ASM withdrawal group compared with the ASM continuation group. The lack of a statistical difference may be explained by the small sample size. Larger studies are needed to confirm these findings. Our results suggest that ASM withdrawal should be initiated cautiously and only when necessary. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that withdrawal of ASM does not significantly increase the risk of recurrent seizures in patients with glioma with stable disease and no seizures for >1 year. Confidence intervals do not exclude a clinically important increased risk of seizures.
引用
- van der Meer PB, Kerkhof M, Dirven L, et al. Long-Term Follow-Up Results of Antiseizure Medication Withdrawal in Grade 2 and 3 Glioma Patients: A Prospective Observational Study. Neurology. 2025. PMID: 40300122. doi:10.1212/WNL.0000000000213590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。